Please use this identifier to cite or link to this item: https://biore.bio.bg.ac.rs/handle/123456789/7763
DC FieldValueLanguage
dc.contributor.authorZakic, Tamaraen_US
dc.contributor.authorJevtic, Jelenaen_US
dc.contributor.authorVukobratovic, Majaen_US
dc.contributor.authorDjuric, Strahinjaen_US
dc.contributor.authorGolić, Igoren_US
dc.contributor.authorKorać, Aleksandraen_US
dc.contributor.authorPekovic-Vaughan, Vanjaen_US
dc.contributor.authorJankovic, Aleksandraen_US
dc.contributor.authorKorać, Batoen_US
dc.date.accessioned2025-08-18T09:10:35Z-
dc.date.available2025-08-18T09:10:35Z-
dc.date.issued2025-07-18-
dc.identifier.issn08915849-
dc.identifier.urihttps://biore.bio.bg.ac.rs/handle/123456789/7763-
dc.description.abstractThe redox-based two-way communication between breast cancer cells and their tumour microenvironment (TME) contributes significantly to the establishment of the malignant phenotype. Due to its well-established role in redox-metabolic reprogramming, Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) has emerged as a potentially key player in the bilateral interaction between breast cancer cells and cancer-associated adipose tissue (CAAT), the main cellular component of the TME. In this study, we used an orthotopic model of Nrf2+/+ luminal type B breast cancer in wild-type (WT) mice and mice lacking functional Nrf2 (Nrf2KO) to investigate the role of Nrf2-driven redox coupling between breast cancer and CAAT. To this end, we examined the expression profiles, localisation, and activity of the main antioxidant defence (AD) enzymes in breast tumour tissue in the Nrf2+/+ or Nrf2-/- host environment at different phases of early tumour growth. In addition, we analysed key enzymes involved in nicotinamide adenine dinucleotide phosphate (NADPH) metabolism. We demonstrate the establishment of a distinct redox profile of breast cancer cells in the Nrf2-/- TME when compared to WT TME. Furthermore, the activity and protein levels of AD enzymes in CAAT showed both Nrf2-dependent and/or tumour-dependent changes. Taken together, these results highlight the importance of Nrf2-driven modulations in the host TME for establishing the redox profile of breast cancer. Moreover, the initial phase of early tumour growth appears most susceptible to the absence of functional Nrf2 in the host TME, thus providing a new potential therapeutic target point for breast cancer therapy.en_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofFree radical biology & medicineen_US
dc.subjectAntioxidant defenceen_US
dc.subjectBreast canceren_US
dc.subjectCancer-associated adipose tissueen_US
dc.subjectNrf2en_US
dc.subjectRedox reprogrammingen_US
dc.subjectTumour microenvironmenten_US
dc.titleNrf2-driven redox coupling of tumour and associated adipose tissue during early tumour growth in an orthotopic breast cancer modelen_US
dc.typeJournal Articleen_US
dc.identifier.doi10.1016/j.freeradbiomed.2025.07.027-
dc.identifier.pmid40684924-
dc.identifier.scopus2-s2.0-105011080121-
dc.identifier.urlhttps://api.elsevier.com/content/abstract/scopus_id/105011080121-
dc.description.rankM21aen_US
dc.description.impact8.2en_US
dc.description.startpage63en_US
dc.description.endpage79en_US
dc.relation.issn0891-5849en_US
dc.description.volume239en_US
item.grantfulltextnone-
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
crisitem.author.deptChair of Cell and Tissue Biology-
crisitem.author.deptChair of Cell and Tissue Biology-
crisitem.author.orcid0000-0001-5944-5053-
crisitem.author.orcid0000-0002-3044-9963-
crisitem.author.orcid0000-0001-5272-579X-
crisitem.author.parentorgInstitute of Zoology-
crisitem.author.parentorgInstitute of Zoology-
Appears in Collections:Journal Article
Show simple item record

SCOPUSTM   
Citations

7
checked on Nov 10, 2026

Page view(s)

85
checked on Nov 10, 2026

Google ScholarTM

Check

Altmetric

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.